Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Roche maintains “strong growth” in third quarter

Roche maintains “strong growth” in third quarter

21st October 2008

Roche has maintained sustained growth during the third quarter of 2008, its chief executive officer said today.

Severin Schwan made his comments as the firm announced its financial results for the first nine months of the year.

He said: “The Roche Group maintained its strong growth in the third quarter. Sales by both the pharmaceuticals and diagnostics divisions advanced at double-digit rates in local currencies, clearly outgrowing their respective markets.”

As a result of this performance, Mr Schwan said Roche expects a “good” full-year result, confirming its outlook for 2008.

He also stated the firm is pleased that the recently-acquired Ventana business “continues to exceed expectations” and that the integration process is now at an advanced stage.

Barring unforeseen events – and based in strong sales growth over the first nine months of the year – Roche confirmed its targets for the full-year. Excluding Tamiflu pandemic sales to corporations and governments, the firm anticipates a high single-digit increase in group sales.

Other highlights of the results include group sales increasing by ten per cent in local currencies to 33.2 billion Swiss francs (16.8 billion pounds).

Earlier this month, Roche, Genentech and Glycart announced they would enter into a collaboration agreement for a potential new cancer therapy.

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.